LENSAR, Inc.

Stage 1 · Basing · week 10

As of Oct 22, 2026, LENSAR is in Stage 1, the basing phase, now in week 10 (since Aug 14, 2026). It closed at $6.02, 52.7% below its 52-week high and below its 200-day average, which is falling.

$6.02

+5.80% today

$74.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is LNSR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 32w

S3 18w

S4 16w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 8w → S4 10w → S1 4w → S2 9w → S3 9w → S2 12w → S3 2w → S2 2w → S3 3w → S2 32w → S3 18w → S4 16w → S1 7w → S4 15w → S1 5w → S4 1w → S1 10w current

Total tracked: 165 weeks across 18 stage runs.

LNSR among Medical Devices89th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…89	LNSRLENSAR, Inc.	Stage 1 · wk 10	23	−15.8%

vs 52W High

-52.7%

$5.01 lo$12.73 hi

52.7% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 10

1w13w26w

Week 10, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-21.0%

200 DMA: $7.62 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

1.34x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.8%

+7.5%

+14.4%

YTD

-48.1%

-50.9%

Scan Membership

Breakout Watch

Latest: 2024-10-23

8 appearances in last 60 days. First seen: 2021-07-20.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 10 · Vol 1.34x

2026-10-21S1

Wk 10 · Vol 0.21x

2026-10-20S1

Wk 10 · Vol 0.42x

2026-10-19S1

Wk 10 · Vol 0.49x

2026-10-16S1

Wk 9 · Vol 0.63x

2026-10-15S1

Wk 9 · Vol 0.34x

2026-10-14S1

Wk 9 · Vol 0.37x

2026-10-13S1

Wk 9 · Vol 0.20x

2026-10-12S1

Wk 9 · Vol 0.36x

2026-10-09S1

Wk 8 · Vol 0.12x

2026-10-08S1

Wk 8 · Vol 0.20x

2026-10-07S1

Wk 8 · Vol 0.26x

Moving averages & range

50 DMA

$7.39

200 DMA

$7.62

52W High

$12.73

52W Low

$5.01

5D Low

$5.69

Resistance levels (recent highs)

20d High

$6.92

60d High

$9.23

120d High

$9.23

250d High

$12.73

Next resistance

+15.0%

to 20d High

P/E (TTM)

33.4

Forward -11.8

ROE

+357.3%

Profit margin +57.6%

Dividend Yield

0.00%

P/B 5.0

LENSAR: quick answers

What stage is LENSAR in?

As of Oct 22, 2026, LENSAR (LNSR) is in Stage 1, the basing phase. It entered Stage 1 on Aug 14, 2026 and is in week 10. What the four stages mean

Is LENSAR in an uptrend?

Not yet. LENSAR is in Stage 1, a base that can come before an uptrend. It trades 21.0% below its 200-day average, which is falling.

How far is LENSAR from its 52-week high?

LENSAR closed at $6.02 on Oct 22, 2026, 52.7% below its 52-week high of $12.73. Its 52-week low is $5.01.

How has LENSAR performed over the past year?

As of Oct 22, 2026, LENSAR is down 50.9% over the past year and down 48.1% so far in 2026.

Which sector and industry is LENSAR in?

LENSAR is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.